NeuroMetrix Company Profile

07:03 EST 14th December 2018 | BioPortfolio

NeuroMetrix, Inc. was founded in June 1996 as a spin-off from the Harvard-M.I.T. Division of Health Sciences and Technology. The Company’s mission is to: Create value for our customers by developing innovative neurological diagnostic and therapeutic solutions that maximize quality of care and economic outcomes Produce a superior return on investment for our shareholders Provide our employees with an opportunity for growth so that they may realize their professional potential The Company is accomplishing these goals by utilizing its proprietary technology platform and its core competency in biomedical engineering, neurophysiology and information technology to develop and commercialize a line of novel neurological diagnostic tests and therapeutic interventions. The key elements of the Company's proprietary technology are: Advanced biosensors that communicate bioelectrical signals between physiological tissue, such as peripheral nerves, and electronic instruments. Sophisticated bioelectronic instruments interface with the biosensors and enable diagnostic and therapeutic procedures. Biomedical signal processing, automation and analysis algorithms. Informatics and decision support software that maximizes clinical utility. Markets At the present time, the Company is focused on the tremendous unmet clinical need in point-of-service neurodiagnostic testing created by tens of millions of annual patient visits related to nerve pathology, as well as in very high rates of nerve related repetitive stress disorders in many industries. The Company’s flagship product, the NC-stat® is a nerve conduction-testing platform that has been on the market since 2000. The NC-stat is used by orthopedic surgeons, neurosurgeons, neurologists, physiatrists, rheumatologists, internal medicine physicians, occupational health physicians, pain medicine physicians, general practitioners, and others, to assist in the diagnosis or exclusion of peripheral nerve disorders.


62 Fourth Ave
United States of America


Phone: 781-890-9989

News Articles [14 Associated News Articles listed on BioPortfolio]

NeuroMetrix shares pop after receiving milestone payment under tie-up with GlaxoSmithKline

NeuroMetrix has ceded ownership of its Quell technology for markets outside the US to Glaxo's consumer health care division

$3.8M milestone payment secured by NeuroMetrix under GSK partnership

NeuroMetrix has obtained a milestone payment worth $3.8 million from GlaxoSmithKline Consumer Healthcare after it met the fir -More- 

GSK makes $3.8M milestone payment to NeuroMetrix

GlaxoSmithKline has made a second milestone payment, valued at $3.8 million, to NeuroMetrix under an agreement reached in Jan -More- 

NeuroMetrix Announces Issuance of New U.S. Patent for DPNCheck Point-of-Care Neuropathy Test Technology

NeuroMetrix (Nasdaq:NURO) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,004,445. The patent covers novel technology that enhances DPNCheck® device performance by ...

NeuroMetrix Announces DPNCheck Collaboration Agreement with Fukuda Denshi for Japan Market

NeuroMetrix (Nasdaq:NURO), announced today that it had executed a distribution agreement with Fukuda Denshi for DPNCheck, the Company’s  rapid, point-of-care test for diabetic peripheral neuropathy...

NeuroMetrix Reports Agreement with GSK Healthcare on 2019 Quell Joint Development Program and Modification to Strategic Collaboration

NeuroMetrix (Nasdaq:NURO) today reported momentum in its strategic collaboration with GSK Consumer Healthcare. As quoted in the press release: Under terms of the collaboration entered into in the firs...

Can NeuroMetrix Stop Its Cash Burn?

NeuroMetrix Inc.'s (NURO) CEO Shai Gozani on Q2 2018 Results - Earnings Call Transcript

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]

NeuroMetrix, Inc.

NeuroMetrix is a science-based health care company transforming patient care through neurotechnology. To date, our focus has been primarily on the assessment of neuropathies. We a...


NeuroMetrix, Inc. was founded in June 1996 as a spin-off from the Harvard-M.I.T. Division of Health Sciences and Technology. The Company’s mission is to: Create value for our customers by developi...

More Information about "NeuroMetrix" on BioPortfolio

We have published hundreds of NeuroMetrix news stories on BioPortfolio along with dozens of NeuroMetrix Clinical Trials and PubMed Articles about NeuroMetrix for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NeuroMetrix Companies in our database. You can also find out about relevant NeuroMetrix Drugs and Medications on this site too.

Quick Search


Relevant Topics

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Corporate Database Quicklinks

Searches Linking to this Company Record